Clinical trials
Glucose Metabolism Disorders trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Unknown status | 7 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 2 |
| RenJi Hospital | 2 |
| Shandong Provincial Hospital | 2 |
| Sun Yat-sen University | 2 |
| Westlake University | 2 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 1 |
| Daewoong Pharmaceutical Co. LTD. | 1 |
| Heart Health Research Center | 1 |
| Hepatopancreatobiliary Surgery Institute of Gansu Province | 1 |
| Huashan Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Metabolism Disorders | 19 |
| Endocrine System Diseases | 8 |
| Metabolic Diseases | 8 |
| Diabetes Mellitus | 7 |
| Diabetes Mellitus, Type 2 | 7 |
| Lipid Metabolism Disorders | 5 |
| Autoimmune Diseases | 2 |
| Diabetes Mellitus, Type 1 | 2 |
| Hyperglycemia | 2 |
| Immune System Diseases | 2 |
Trials
Showing 76 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.